Unknown

Dataset Information

0

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.


ABSTRACT: BACKGROUND:Aurora kinase A (AURKA) is commonly overexpressed in sarcoma. The inhibition of AURKA by shRNA or by a specific AURKA inhibitor blocks in vitro proliferation of multiple sarcoma subtypes. MLN8237 (alisertib) is a novel oral adenosine triphosphate-competitive AURKA inhibitor. PATIENTS AND METHODS:This Cancer Therapy Evaluation Program-sponsored phase II study of alisertib was conducted through the Alliance for Clinical Trials in Oncology (A091102). Patients were enrolled into histology-defined cohorts: (i) liposarcoma, (ii) leiomyosarcoma, (iii) undifferentiated sarcoma, (iv) malignant peripheral nerve sheath tumor, or (v) other. Treatment was alisertib 50 mg PO b.i.d. d1-d7 every 21 days. The primary end point was response rate; progression-free survival (PFS) was secondary. One response in the first 9 patients expanded enrollment in a cohort to 24 using a Simon two-stage design. RESULTS:Seventy-two patients were enrolled at 24 sites [12 LPS, 10 LMS, 11 US, 10 malignant peripheral nerve sheath tumor (MPNST), 29 Other]. The median age was 55 years; 54% were male; 58%/38%/4% were ECOG PS 0/1/2. One PR expanded enrollment to the second stage in the other sarcoma cohort. The histology-specific cohorts ceased at the first stage. There were two confirmed PRs in the other cohort (both angiosarcoma) and one unconfirmed PR in dedifferentiated chondrosarcoma. Twelve-week PFS was 73% (LPS), 44% (LMS), 36% (US), 60% (MPNST), and 38% (Other). Grade 3-4 adverse events: oral mucositis (12%), anemia (14%), platelet count decreased (14%), leukopenia (22%), and neutropenia (42%). CONCLUSIONS:Alisertib was well tolerated. Occasional responses, yet prolonged stable disease, were observed. Although failing to meet the primary RR end point, PFS was promising. TRIAL REGISTRATION ID:NCT01653028.

SUBMITTER: Dickson MA 

PROVIDER: S-EPMC5035789 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.

Dickson M A MA   Mahoney M R MR   Tap W D WD   D'Angelo S P SP   Keohan M L ML   Van Tine B A BA   Agulnik M M   Horvath L E LE   Nair J S JS   Schwartz G K GK  

Annals of oncology : official journal of the European Society for Medical Oncology 20160808 10


<h4>Background</h4>Aurora kinase A (AURKA) is commonly overexpressed in sarcoma. The inhibition of AURKA by shRNA or by a specific AURKA inhibitor blocks in vitro proliferation of multiple sarcoma subtypes. MLN8237 (alisertib) is a novel oral adenosine triphosphate-competitive AURKA inhibitor.<h4>Patients and methods</h4>This Cancer Therapy Evaluation Program-sponsored phase II study of alisertib was conducted through the Alliance for Clinical Trials in Oncology (A091102). Patients were enrolled  ...[more]

Similar Datasets

| S-EPMC7543335 | biostudies-literature
| S-EPMC4110881 | biostudies-literature
| S-EPMC6982547 | biostudies-literature
2021-08-20 | GSE174765 | GEO
2008-01-31 | GSE5851 | GEO
| S-EPMC6517396 | biostudies-literature
| S-EPMC4468408 | biostudies-literature
| S-EPMC4229392 | biostudies-literature
| S-EPMC6058323 | biostudies-literature
| S-EPMC5943671 | biostudies-literature